NOT-AG-24-076: Notice of Early Expiration of PAR-23-081, "Early and Late Stage Clinical Trials for the Spectrum of Alzheimers Disease/Alzheimers Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)"

Notice of Early Expiration of PAR-23-081, "Early and Late Stage Clinical Trials for the Spectrum of Alzheimer’s Disease/Alzheimer’s Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)"

Notice Number:

NOT-AG-24-076

Key Dates

Release Date:

November 7, 2024

Related Announcements

December 23, 2022 - Early and Late Stage Clinical Trials for the Spectrum of Alzheimer’s Disease/Alzheimer’s Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional). See NOFO PAR-23-081.

Issued by

National Institute on Aging (NIA)

Purpose

The purpose of this Notice is to inform the extramural community of the early expiration of PAR-23-081, "Early and Late Stage Clinical Trials for the Spectrum of Alzheimer’s Disease/Alzheimer’s Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)," effective immediately. The Key Dates section of the NOFO has been modified to change the Expiration Date from January 08, 2025 to November 7, 2024.

Inquiries

Please direct all inquiries to:

Laurie Ryan, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-9350
Email: [email protected]